[1]
|
Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States[J]. JAMA Oncol, 2017, 3: 1335-1342. doi: 10.1001/jamaoncol.2017.0589 |
[2]
|
Fang C, Wang W, Zhang Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China[J]. Chin J Cancer, 2017, 36: 51. doi: 10.1186/s40880-017-0218-3 |
[3]
|
Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Func-tional Pancreatic Neuroendocrine Tumors[J]. Neuroendocrinology, 2016, 103: 153-171. doi: 10.1159/000443171 |
[4]
|
Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis[J]. Front Endocrinol (Lausanne), 2019;10: 339. doi: 10.3389/fendo.2019.00339 |
[5]
|
Puliani G, Di Vito V, Feola T, et al. NETest: A Systematic Review Focusing on the Prognostic and Predictive Role[J]. Neuroendocrinology, 2022, 112: 523-536. doi: 10.1159/000518873 |
[6]
|
Malczewska A, Kos-Kudła B, Kidd M, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors[J]. Adv Med Sci, 2020, 65: 18-29. doi: 10.1016/j.advms.2019.10.002 |
[7]
|
Chen L, Guo Y, Zhang Y, et al. Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors[J]. Endoscopy, 2021, 53: 702-709. doi: 10.1055/a-1274-0161 |
[8]
|
Luo Y, Chen J, Huang K, et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?[J]. BMC Cancer, 2017, 17: 154. doi: 10.1186/s12885-017-3150-7 |
[9]
|
Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_GETNE1504 study)[J]. Br J Cancer, 2019, 121: 537-544. doi: 10.1038/s41416-019-0558-7 |
[10]
|
Chen L, Wang W, Jin K, et al. Special issue "the advane of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors[J]. Int J Cancer, 2023, 152: 90-99. doi: 10.1002/ijc.34294 |
[11]
|
Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG[J]. Cancer, 2008, 112: 2447-2455. doi: 10.1002/cncr.23469 |
[12]
|
Panagiotidis E, Alshammari A, Michopoulou S, et al. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors[J]. J Nucl Med, 2016, 58: 91-96. |
[13]
|
Rinzivillo M, Partelli S, Prosperi D, et al. Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms[J]. Oncologist, 2018, 23: 186-192. doi: 10.1634/theoncologist.2017-0278 |
[14]
|
Kim YI, Yoo C, Oh SJ, et al. Tumour-to-liver ratio determined by[(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours[J]. EJNMMI Res, 2020, 10: 63. doi: 10.1186/s13550-020-00651-z |
[15]
|
Kuik WJ, Kema IP, Brouwers AH, et al. In vivo biodistribution of no-carrier-added 6-18F-fluoro-3, 4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleo-philic substitution approach, compared with carrier-added (18F-DOPA), prepared by conventional electrophilic substitution[J]. J Nucl Med, 2015, 56: 106-112. doi: 10.2967/jnumed.114.145730 |
[16]
|
Piccardo A, Lopci E, Conte M, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study[J]. Eur J Nucl Med Mol Imaging, 2012, 39: 57-71. doi: 10.1007/s00259-011-1938-2 |
[17]
|
Luo Y, Pan Q, Yao S, et al. Glucagon-like Peptide-1 Receptor PET/CT with 68Ga-NOTA-exendin-4 for Detecting Localized Insulinoma: a Prospective Cohort Study[J]. J Nucl Med, 2016, 57: 715-720. doi: 10.2967/jnumed.115.167445 |
[18]
|
WHO Classification of Tumours Editorial Board. WHO classification of tumours, 5th Edition, Volume 1: Digestive System Tumours[M]. Lyon: IARC Press, 2019. |
[19]
|
WHO Classification of Tumours Editorial Board. WHO Classification of Tumours, 5th Edition, Volume 5: Thoracic Tumours[M]. Lyon: IARC Press, 2021. |
[20]
|
Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart[J]. J Thorac Oncol, 2015, 10: 1240-1242. doi: 10.1097/JTO.0000000000000663 |
[21]
|
Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal[J]. Mod Pathol, 2018, 31: 1770-1786. doi: 10.1038/s41379-018-0110-y |
[22]
|
Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms[J]. Endocr Pathol, 2022, 33: 115-154. doi: 10.1007/s12022-022-09708-2 |
[23]
|
Chivukula SV, Tierney JF, Hertl M, et al. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over-or undertreating patients?[J]. Surgery, 2020, 167: 180-186. doi: 10.1016/j.surg.2019.04.061 |
[24]
|
Dong DH, Zhang XF, Poultsides G, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm after curative resection: A multi-institutional study of 392 cases[J]. J Surg Oncol, 2019, 120: 1071-1079. doi: 10.1002/jso.25716 |
[25]
|
Lopez-Aguiar AG, Zaidi MY, Beal EW, et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: An eight-institution study of 695 patients from the US neuroendocrine tumor study group[J]. Ann Surg Oncol, 2019, 26: 2517-2524. doi: 10.1245/s10434-019-07367-y |
[26]
|
Guarneri G, de Mestier L, Landoni L, et al. Prognostic role of examined and positive lymph nodes after distal pancreatectomy for non-functioning neuroendocrine neoplasms[J]. Neuroendocrinology, 2021, 111: 728-738. doi: 10.1159/000509709 |
[27]
|
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371: 224-233. doi: 10.1056/NEJMoa1316158 |
[28]
|
Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroen-docrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol, 2009, 27: 4656-4663. doi: 10.1200/JCO.2009.22.8510 |
[29]
|
Liu Y, Liu H, Chen W, et al. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden[J]. Cancer Med, 2022, 11: 2588-2600. doi: 10.1002/cam4.4628 |
[30]
|
Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?[J]. J Hepatol, 2007, 47: 460-466. doi: 10.1016/j.jhep.2007.07.004 |
[31]
|
中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022, 32: 545-580. Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. Zhongguo Aizheng Zazhi, 2022, 32: 545-580. |
[32]
|
Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas[J]. Neuroendocrinology, 2016, 103: 186-194. doi: 10.1159/000443172 |
[33]
|
National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors (Version 2021)[EB/OL]. [2021-06-18]. https://www.nccn.org/guidelines/guidelines-detail?cate-gory=1&id=1448. |
[34]
|
Bongiovanni A, Liverani C, Foca F, et al. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis[J]. Neuroendocrinology, 2021, 111: 895-906. doi: 10.1159/000513218 |
[35]
|
Wang W, Zhang Y, Peng Y, et al. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolo-mide Regimen in Neuroendocrine Neoplasms: A Retrospec-tive Multicenter Study[J]. Neuroendocrinology, 2021, 111: 752-763. doi: 10.1159/000510159 |
[36]
|
Apostolidis L, Dal Buono A, Merola E, et al. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)[J]. Cancers, 2021, 13: 1936. doi: 10.3390/cancers13081936 |
[37]
|
Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 379: 2220-2229. doi: 10.1056/NEJMoa1809064 |
[38]
|
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394: 1929-1939. doi: 10.1016/S0140-6736(19)32222-6 |